Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mycophenolate Mofetil

FDA-approved product (capsule, oral), marketed as Cellcept, Mycophenolate Mofetil, Myhibbin and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Mycophenolate Mofetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Delayed Graft Function
  • Immune system disease
  • Multiple sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective immunosuppressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mycophenolate Mofetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mycophenolate Mofetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients

    NCT00717678 · start 2007-12

    Registered record
    Registry ID
    NCT00717678
    Conditions
    Kidney Transplantation; Transplantation Immunology; Host vs Graft Reaction
    Interventions
    Prograf-XL; Prograf; MMF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2010-04
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation; Transplantation Immunology; Host vs Graft Reaction
    InterventionPrograf-XL; Prograf; MMF
    PhasePhase 3
    Registry statusCompleted

  • A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.

    NCT00545402 · start 2007-11

    Registered record
    Registry ID
    NCT00545402
    Conditions
    Liver Transplantation
    Interventions
    Mycophenolate mofetil, adjusted dose; Tacrolimus; Corticosteroids, IV; Mycophenolate mofetil, Standard dose; Corticosteroids, PO
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-11
    Completion
    2011-07
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionMycophenolate mofetil, adjusted dose; Tacrolimus; Corticosteroids, IV; Mycophenolate mofetil, Standard dose +1 more
    PhasePhase 4
    Registry statusCompleted

  • A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation

    NCT00481819 · start 2007-07

    Registered record
    Registry ID
    NCT00481819
    Conditions
    Kidney Transplantation
    Interventions
    FK506MR; Prograf; Mycophenolate Mofetil; Methylprednisolone; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-03
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation
    InterventionFK506MR; Prograf; Mycophenolate Mofetil; Methylprednisolone +1 more
    PhasePhase 3
    Registry statusCompleted

  • Observational Registry Study of Renal Transplant Patients

    NCT01284257 · start 2007-06

    Registered record
    Registry ID
    NCT01284257
    Conditions
    Kidney Transplant
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2007-06
    Completion
    2010-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Oral Paricalcitol in Kidney Transplant Recipients

    NCT00587158 · start 2007-01

    Registered record
    Registry ID
    NCT00587158
    Conditions
    Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary
    Interventions
    Paricalcitol; Corticosteroid Avoidance Immune Suppression Protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-01
    Completion
    2011-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary
    InterventionParicalcitol; Corticosteroid Avoidance Immune Suppression Protocol
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant

    NCT00446251 · start 2006-12

    Registered record
    Registry ID
    NCT00446251
    Conditions
    Kidney Failure, Chronic; Diabetic Nephropathies; Glomerulonephritis, IGA; Hypertension, Renal
    Interventions
    Rituximab; Mycophenolate mofetil (MMF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-12
    Completion
    2008-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Failure, Chronic; Diabetic Nephropathies; Glomerulonephritis, IGA; Hypertension, Renal
    InterventionRituximab; Mycophenolate mofetil (MMF)
    PhasePhase 2
    Registry statusCompleted

  • Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

    NCT00351377 · start 2006-06

    Registered record
    Registry ID
    NCT00351377
    Conditions
    Autoimmune Disease
    Interventions
    Enteric-coated Mycophenolate Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2009-06
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutoimmune Disease
    InterventionEnteric-coated Mycophenolate Sodium
    PhasePhase 3
    Registry statusCompleted

  • Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

    NCT00354172 · start 2006-02

    Registered record
    Registry ID
    NCT00354172
    Conditions
    Leukemia; Myelodysplastic Syndromes
    Interventions
    aldesleukin; filgrastim; natural killer cell (NK) therapy; cyclophosphamide; cyclosporine; fludarabine phosphate; methylprednisolone; mycophenolate mofetil; Umbilical Cord Blood Transplantation (UCBT); Total body irradiation (TBI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-02
    Completion
    2008-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Myelodysplastic Syndromes
    Interventionaldesleukin; filgrastim; natural killer cell (NK) therapy; cyclophosphamide +6 more
    PhasePhase 2
    Registry statusTerminated

  • Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

    NCT00360685 · start 2005-09

    Registered record
    Registry ID
    NCT00360685
    Conditions
    Mucositis; Graft-versus-host Disease
    Interventions
    Tac+MTX; TAC + MMF
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-09
    Completion
    2011-01
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucositis; Graft-versus-host Disease
    InterventionTac+MTX; TAC + MMF
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection

    NCT00133172 · start 2005-07

    Registered record
    Registry ID
    NCT00133172
    Conditions
    Kidney Transplantation
    Interventions
    Tacrolimus; mycophenolate mofetil; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2005-07
    Completion
    2007-03
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation
    InterventionTacrolimus; mycophenolate mofetil; Prednisone
    PhasePhase 4
    Registry statusTerminated

  • Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

    NCT00154310 · start 2005-06

    Registered record
    Registry ID
    NCT00154310
    Conditions
    Renal Transplantation
    Interventions
    Everolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2008-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation
    InterventionEverolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Mmf and Valganciclovir

    NCT00189150 · start 2005-04

    Registered record
    Registry ID
    NCT00189150
    Conditions
    Kidney Transplant Recipient; Heart Transplant Recipient
    Interventions
    Mycophenolate mofetil; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Recipient; Heart Transplant Recipient
    InterventionMycophenolate mofetil; Valganciclovir
    PhasePhase 4
    Registry statusCompleted

  • Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

    NCT00118352 · start 2005-03

    Registered record
    Registry ID
    NCT00118352
    Conditions
    Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; N
    Interventions
    alemtuzumab; total-body irradiation; fludarabine phosphate; cyclosporine; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; graft versus host disease prophylaxis/therapy; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2015-05-26
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma +21 more
    Interventionalemtuzumab; total-body irradiation; fludarabine phosphate; cyclosporine +5 more
    PhasePhase 2
    Registry statusCompleted

  • Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

    NCT00075829 · start 2003-12

    Registered record
    Registry ID
    NCT00075829
    Conditions
    Multiple Myeloma
    Interventions
    One Autologous Transplant; Non-Myeloablative Allogeneic Transplant; Second Autologous Transplant; Thalidomide; Dexamethasone; Observation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12
    Completion
    2013-03
    Enrolment
    710

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionOne Autologous Transplant; Non-Myeloablative Allogeneic Transplant; Second Autologous Transplant; Thalidomide +2 more
    PhasePhase 3
    Registry statusCompleted

  • Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

    NCT00241059 · start 2002-08

    Registered record
    Registry ID
    NCT00241059
    Conditions
    Renal Transplantation
    Interventions
    Enteric-Coated Mycophenolate Sodium (EC-MPS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-08
    Completion
    2005-01
    Enrolment
    183

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation
    InterventionEnteric-Coated Mycophenolate Sodium (EC-MPS)
    PhasePhase 4
    Registry statusCompleted